Arrowstreet Capital’s NovoCure NVCR Stock Holding History

Arrowstreet Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4M	Buy	158,173 +130,043	+462%	+$1.97M	﹤0.01%	1491
2026 Q1	$307K	Buy	+28,130	New	+$351K	﹤0.01%	1729
2022 Q3	–	Sell	-30,483	Closed	-$2.12M	–	1410
2022 Q2	$2.12M	Buy	+30,483	New	+$2.3M	﹤0.01%	769
2020 Q3	–	Sell	-6,400	Closed	-$380K	–	2459
2020 Q2	$380K	Buy	+6,400	New	+$421K	﹤0.01%	2037
2020 Q1	–	Sell	-164,205	Closed	-$13.8M	–	2041
2019 Q4	$13.8M	Buy	+164,205	New	+$13.3M	0.03%	503
2019 Q2	–	Sell	-87,000	Closed	-$4.19M	–	1608
2019 Q1	$4.19M	Buy	+87,000	New	+$4.19M	0.01%	856

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Arrowstreet Capital's NVCR Position: Q2 2026 in Review

Arrowstreet Capital increased its NovoCure (NVCR) stake by 462% in Q2 2026, buying an estimated $1.97M and bringing the position to 158,173 shares worth $2.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1491.

Arrowstreet Capital first reported a position in NVCR in Q1 2019 and has held it in 6 quarters since. The position peaked at $13.8M in Q4 2019. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Arrowstreet Capital held 158,173 shares of NovoCure worth $2.4M as of Q2 2026.
Arrowstreet Capital bought 130,043 NovoCure shares in Q2 2026, an estimated $1.97M.
NovoCure made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1491 holding.
Arrowstreet Capital first reported a position in NovoCure in Q1 2019 and has held it in 6 quarters since.
Arrowstreet Capital's NovoCure position peaked at $13.8M in Q4 2019.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.